Press release BoxID: 166615 (VITA 34 AG Deutschland)
  • VITA 34 AG Deutschland
  • Deutscher Platz 5a
  • 04103 Leipzig
  • Contact person
  • Axel Mühlhaus
  • +49 (69) 90550552

VITA 34 International AG increases revenues in Q1 2008, setting the course for further growth

(PresseBox) (Leipzig, ) .
- Revenues of EUR 3.6 million.
- EBIT of EUR -0.3 million as planned
- Period result in the group of EUR 0.1 million.
- Clearly upturn in international revenues planned.

Revenues of VITA 34 International AG (ISIN DE000A0BL849), as the holding of the leading company for storing umbilical cord blood in Germany, VITA 34, rose to EUR 3.6 million in Q1 2008 following EUR 3.5 million in the equivalent period of the previous year. VITA 34 thus looks back on its best first quarter in the more than ten years of the company s history. The number of stored stem cell preparations totaled 2,453 as compared to 2,446 in the strong prior year period.

Due to the scheduled 40% increase in expenditure for sales and marketing, EBIT from continued operations amounted to EUR -0.3 million compared with EUR 0.3 million one year before. At EUR 0.1 million, the group result including discontinued operations was slightly positive. In Q1 of the previous year, profit from the discontinued operation amounting to EUR 1.3 million resulted in a net result of EUR 1.4 million.

The equity ratio of the group rose steadily, reaching 64%, three percentage points more than on December 31, 2007.

VITA 34 anticipates that the new marketing and sales strategy which started in the previous year will make an increasing impact from the middle of 2008, in line with planning. As the undisputed market leader in the German-speaking countries, VITA 34 plans a clear, strong increase in international operating revenues in the current year. One factor making a contribution here is the very successful partnership with the Spanish company, Secuvita